Showing 3111-3120 of 5773 results for "".
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgeryhttps://modernod.com/news/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-for-the-treatment-of-decreased-va-under-low-light-conditions-following-keratorefractive-surgery/2482227/Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 phase 3 registration study evaluating phentolamine ophthalmic solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery. The LY
- Oculis Appoints Snehal Shah, PharmD, as President of Research & Developmenthttps://modernod.com/news/oculis-appoints-snehal-shah-pharmd-as-president-of-research-development/2482225/Oculis announced the appointment of Snehal Shah, PharmD, executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D. In this new role, Dr. Shah will be responsible for leading research and developmen
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als
- FDA Approves Ocugen's IND Amendment to Initiate Phase 3 Trial for RP Gene Therapyhttps://modernod.com/news/fda-approves-ocugens-ind-amendment-to-initiate-phase-3-trial-for-rp-gene-therapy/2482220/Ocugen announced that the FDA has cleared the company’s investigational new drug (IND) amendment to initiate a phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “The initiation of the OCU400 phase
- New VR Solution Aims to Democratize Ophthalmic Surgical Traininghttps://modernod.com/news/new-vr-solution-aims-to-democratize-ophthalmic-surgical-training/2482216/At the ASCRS annual meeting in Boston, Orbis International and FundamentalVR launched a new immersive virtual reality (VR) training solution designed for use in low- and middle-income countries. The tool is built to support students and residents learning to perform surgery to trea
- TheiaNova Selected as Finalist at Eyecelerator for Keratoconus Therapy; Launches Capital Raise for Clinical Trialshttps://modernod.com/news/theianova-selected-as-finalist-at-eyecelerator-for-keratoconus-therapy-launches-capital-raise-for-clinical-trials/2482215/New Zealand-based TheiaNova has delivered the company’s pitch as a finalist in the renowned Eyecelerator event in Boston. At the Eyecelerator event, where TheiaNova participated as a finalist, CEO Carissa Fonseca announced the company’s efforts to raise $10 million 
- ViaLase to Present New Clinical Data at ASCRShttps://modernod.com/news/vialase-to-present-new-clinical-data-at-ascrs/2482214/ViaLase announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston, Massachusetts. ViaLase will be exhibiting onsite at boot